economic
Archived signal
Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
Reported by The Hindu
Read the complete report at The Hindu ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
1 recorded state
Signal first indexedP1 · 68% quality · 1 source